ANDA 203265, held by Noven Pharms Inc. Lidocaine.
As of Nov 15, 2026, ANDA 203265 (Lidocaine), held by Noven Pharms Inc, was first approved by FDA on Dec 1, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 1, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine5% ยท patch;topical | Lidocaine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
